Mast cells inhibit CD8 + T cell-mediated rejection of a malignant fibrous histiocytoma-like tumor: Involvement of Fas-Fas Ligand axis

American Journal of Immunology

Volumn 5, Issue 3, 2009, Pages 89-97

  Furukawa, Hiroshi ^a,b   Kitazawa, Hiroshi ^a   Kaneko, Izumi ^a   Kikuchi, Koichi ^a   Tohma, Shigeto ^b   Nose, Masato ^c   Ono, Masao ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fas; Fasl; Mast cell; Syngeneic tumor rejection

Indexed keywords

EID: 84859902957     PISSN: 1553619X     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajisp.2009.89.97     Document Type: Article

References (27)

1. Abraham, S.N. and R. Malaviya, 1997. Mast cells in infection and immunity. Infect. Immun., 65: 3501-3508. http://iai.asm.org/cgi/content/citation/65/9/3501
2. Lu, L.F., E.F. Lind, D.C. Gondek, K.A. Bennett and M.W. Pino-Lagos et al., 2006. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature, 442: 997-1002. DOI: 10.1038/nature05010
3. Nakayama, T., L. Yao and G. Tosato, 2004. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin. Invest., 114: 1317-1325. DOI: 10.1172/JCI22089
4. Wedemeyer, J. and S.J. Galli, 2005. Decreased susceptibility of mast cell-deficient KitW/KitW-v mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. Lab Invest., 85: 388-396. DOI: 10.1038/labinvest.3700232
5. Sinnamon, M.J., K.J. Carter, L.P. Sims, B. Lafleur, B. Fingleton and L.M. Matrisian, 2008. A protective role for mast cells in intestinal tumorigenesis. Carcinogenesis, 29: 880-886. DOI: 10.1093/carcin/bgn040
6. Andrews, B.S., R.A. Eisenberg, A.N. Theofilopoulos, S. Izui and F.J. Dixon et al., 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med., 148: 1198-1215. http://jem.rupress.org/cgi/content/abstract/148/5/1198
7. Watanabe-Fukunaga, R., C.I. Brannan, N.G. Copeland, N.A. Jenkins and S. Nagata, 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature, 356: 314-317. DOI: 10.1038/356314a0
8. Roths, J.B., E.D. Murphy and E.M. Eicher, 1984. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J. Exp. Med., 159: 1-20. http://jem.rupress.org/cgi/content/abstract/159/1/1
9. Ito, M.R., S. Terasaki, J. Itoh, H. Katoh, S. Yonehara and M. Nose, 1997. Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand. Arthritis Rheum., 40: 1054-1063. http://www.ncbi.nlm.nih.gov/pubmed/9182916
10. Hasegawa, H., M. Kohno, M. Sasaki, A. Inoue and M.R. Ito et al., 2003. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum., 48: 2555-2566. DOI: 10.1002/art.11231
11. Inoue, A., H. Hasegawa, M. Kohno, M.R. Ito and M. Terada et al., 2005. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum., 52: 1522-1533. DOI: 10.1002/art.21007
12. Zhang, M.C., H. Furukawa, K. Tokunaka, K. Saiga and F. Date et al., 2008. Mast cell hyperplasia in the skin of Dsg4-deficient hypotrichosis mice, which are long-living mutants of lupus-prone mice. Immunogenetics, 60: 599-607. DOI: 10.1007/s00251-008-0320-4
13. Komori, H., H. Furukawa, S. Mori, M.R. Ito and M. Ono et al., 2006. A signal adaptor SLAMassociated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice. J. Immunol., 176: 395-400. http://www.jimmunol.org/cgi/content/abstract/176/1/395
14. Furukawa, H., K. Iizuka, J. Poursine-Laurent, N. Shastri and W.M. Yokoyama, 2002. A ligand for the murine NK activation receptor Ly-49D: Activation of tolerized NK cells from beta 2-microglobulin-deficient mice. J. Immunol., 169: 126-136. http://www.jimmunol.org/cgi/content/abstract/169/1/126
15. Hartmann, K., A.L. Wagelie-Steffen, E. von Stebut and D.D. Metcalfe, 1997. Fas (CD95, APO-1) antigen expression and function in murine mast cells. J. Immunol., 159: 4006-4014. http://www.jimmunol.org/cgi/content/abstract/159/8/4006
16. Yoshikawa, H., Y. Nakajima and K. Tasaka, 2000. Enhanced expression of Fas-associated death domain-like IL-1-Converting Enzyme (FLICE)-inhibitory protein induces resistance to Fasmediated apoptosis in activated mast cells. J. Immunol., 165: 6262-6269. http://www.jimmunol.org/cgi/content/abstract/165/11/6262
17. Kankkunen, J.P., I.T. Harvima and A. Naukkarinen, 1997. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int. J. Cancer, 72: 385-388. DOI: 10.1002/(SICI)1097-0215(19970729)72:3<385::AID-IJC1>3.0.CO;2-L
18. Esposito, I., J. Kleeff, S.C. Bischoff, L. Fischer and P. Collecchi et al., 2002. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab. Invest., 82: 1481-1492. http://www.ncbi.nlm.nih.gov/pubmed/12429808
19. Yano, H., M. Kinuta, H. Tateishi, Y. Nakano and S. Matsui et al., 1999. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer, 2: 26-32. DOI: 10.1007/s101200050017
20. Takanami, I., K. Takeuchi and M. Naruke, 2000. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer, 88: 2686-2692. DOI: 10.1002/1097-0142(20000615)88:12<2686::AIDCNCR6> 3.0.CO;2-6
21. Coussens, L.M., W.W. Raymond, G. Bergers, M. Laig-Webster and D. Hanahan, 1999. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev., 13: 1382-1397. http://genesdev.cshlp.org/content/13/11/1382.abstra ct
22. Tanooka, H., Y. Kitamura, T. Sado, K. Tanaka, M. Nagase and S. Kondo, 1982. Evidence for involvement of mast cells in tumor suppression in mice. J. Natl. Cancer Inst., 69: 1305-1309. http://www.ncbi.nlm.nih.gov/pubmed/6982995
23. Burtin, C., C. Ponvert, A. Fray, P. Scheinmann and G. Lespinats et al., 1985. Inverse correlation between tumor incidence and tissue histamine levels in W/WV, WV/+ and +/+ mice. J. Natl. Cancer Inst., 74: 671-674. http://www.ncbi.nlm.nih.gov/pubmed/3856069
24. Schittek, A., H.A. Issa, J.H. Stafford, D. Young, B. Zwilling and A.G. James, 1985. Growth of pulmonary metastases of B16 melanoma in mast cell-free mice. J. Surg. Res., 38: 24-28. http://www.ncbi.nlm.nih.gov/pubmed/3965806
25. Starkey, J.R., P.K. Crowle and S. Taubenberger, 1988. Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int. J. Cancer, 42: 48-52. http://www.ncbi.nlm.nih.gov/pubmed/2455691
26. Dethlefsen, S.M., N. Matsuura and B.R. Zetter, 1994. Mast cell accumulation at sites of murine tumor implantation: Implications for angiogenesis and tumor metastasis. Invasion Metastasis, 14: 395-408. http://www.ncbi.nlm.nih.gov/pubmed/7544776
27. Yeatman, C.F., S.M. Jacobs-Helber, P. Mirmonsef, S.R. Gillespie and L.A. Bouton et al., 2000. Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J. Exp. Med., 192: 1093-1103. http://www.ncbi.nlm.nih.gov/pubmed/11034599